369 related articles for article (PubMed ID: 32281420)
1. Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics.
Jiang YH; Jhang JF; Hsu YH; Ho HC; Wu YH; Kuo HC
Am J Physiol Renal Physiol; 2020 Jun; 318(6):F1391-F1399. PubMed ID: 32281420
[TBL] [Abstract][Full Text] [Related]
2. Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?
Jiang YH; Jhang JF; Kuo HC
Diagnostics (Basel); 2022 Apr; 12(5):. PubMed ID: 35626252
[TBL] [Abstract][Full Text] [Related]
3. Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm.
Jiang YH; Jhang JF; Hsu YH; Ho HC; Wu YH; Kuo HC
Sci Rep; 2021 Jan; 11(1):914. PubMed ID: 33441752
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of Urinary Biomarkers for Assessing Bladder Condition and Histopathology in Patients with Interstitial Cystitis/Bladder Pain Syndrome.
Jiang YH; Jhang JF; Hsu YH; Kuo HC
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233356
[TBL] [Abstract][Full Text] [Related]
5. Urine Oxidative Stress Biomarkers as Novel Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome.
Jiang YH; Jhang JF; Ho HC; Chiou DY; Kuo HC
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885006
[TBL] [Abstract][Full Text] [Related]
6. Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome.
Yu WR; Jiang YH; Jhang JF; Kuo HC
Biomedicines; 2022 May; 10(5):. PubMed ID: 35625885
[TBL] [Abstract][Full Text] [Related]
7. Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions.
Yu WR; Jiang YH; Jhang JF; Kuo HC
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569430
[TBL] [Abstract][Full Text] [Related]
8. Elevated Urine Levels of Macrophage Migration Inhibitory Factor in Inflammatory Bladder Conditions: A Potential Biomarker for a Subgroup of Interstitial Cystitis/Bladder Pain Syndrome Patients.
Vera PL; Preston DM; Moldwin RM; Erickson DR; Mowlazadeh B; Ma F; Kouzoukas DE; Meyer-Siegler KL; Fall M
Urology; 2018 Jun; 116():55-62. PubMed ID: 29580781
[TBL] [Abstract][Full Text] [Related]
9. Local immune response in bladder pain syndrome/interstitial cystitis ESSIC type 3C.
Gamper M; Viereck V; Eberhard J; Binder J; Moll C; Welter J; Moser R
Int Urogynecol J; 2013 Dec; 24(12):2049-57. PubMed ID: 23670165
[TBL] [Abstract][Full Text] [Related]
10. ESSIC criteria for the diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) and comparison with the NIDDK criteria.
Proaño A; Garde G; Garrido G; Mazza O
Arch Esp Urol; 2013 Mar; 66(2):206-14. PubMed ID: 23589598
[TBL] [Abstract][Full Text] [Related]
11. Combination of urinary biomarkers and machine-learning models provided a higher predictive accuracy to predict long-term treatment outcomes of patients with interstitial cystitis/bladder pain syndrome.
Jhang JF; Yu WR; Huang WT; Kuo HC
World J Urol; 2024 Mar; 42(1):173. PubMed ID: 38507059
[TBL] [Abstract][Full Text] [Related]
12. Potential Urine and Serum Biomarkers in Patients with Bladder Pain Syndrome/Interstitial Cystitis.
Wang L; Gao J; Zheng S; Wang Z; Zheng S; Luo Z
Arch Esp Urol; 2024 May; 77(4):353-358. PubMed ID: 38840277
[TBL] [Abstract][Full Text] [Related]
13. Urine nerve growth factor (NGF) level, bladder nerve staining and symptom/problem scores in patients with interstitial cystitis.
Tonyali S; Ates D; Akbiyik F; Kankaya D; Baydar D; Ergen A
Adv Clin Exp Med; 2018 Feb; 27(2):159-163. PubMed ID: 29521057
[TBL] [Abstract][Full Text] [Related]
14. Peptidomics analysis reveals changes in small urinary peptides in patients with interstitial cystitis/bladder pain syndrome.
Abid MSR; Qiu H; Tripp BA; de Lima Leite A; Roth HE; Adamec J; Powers R; Checco JW
Sci Rep; 2022 May; 12(1):8289. PubMed ID: 35585122
[TBL] [Abstract][Full Text] [Related]
15. A genome-scale DNA methylation study in women with interstitial cystitis/bladder pain syndrome.
Bradley MS; Burke EE; Grenier C; Amundsen CL; Murphy SK; Siddiqui NY
Neurourol Urodyn; 2018 Apr; 37(4):1485-1493. PubMed ID: 29363787
[TBL] [Abstract][Full Text] [Related]
16. Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome.
Jiang YH; Peng CH; Liu HT; Kuo HC
PLoS One; 2013; 8(10):e76779. PubMed ID: 24146927
[TBL] [Abstract][Full Text] [Related]
17. Urinary ATP may be a biomarker of interstitial cystitis/bladder pain syndrome and its severity.
Wu Y; He Y; Qi J; Wang S; Wang Z
Biomol Biomed; 2024 Jan; 24(1):170-175. PubMed ID: 37819233
[TBL] [Abstract][Full Text] [Related]
18. Temporally complex inflammatory networks in an animal model reveal signatures for interstitial cystitis and bladder pain syndrome phenotype.
Shah AM; Vodovotz Y; Yoshimura N; Chermansky CJ; Fitzgerald J; Tyagi P
Neurourol Urodyn; 2023 Nov; 42(8):1839-1848. PubMed ID: 37587846
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic overlap in overactive bladder and interstitial cystitis/bladder pain syndrome: development of a new algorithm.
Ackerman AL; Lai HH; Parameshwar PS; Eilber KS; Anger JT
BJU Int; 2019 Apr; 123(4):682-693. PubMed ID: 30253040
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-to-lymphocyte ratio as a promising non-invasive biomarker for symptom assessment and diagnosis of interstitial cystitis/bladder pain syndrome.
Ke H; Zhu L; Wang Q; Xu K
BMC Urol; 2023 Nov; 23(1):180. PubMed ID: 37940904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
